Study of NMD670 for generalized myasthenia gravis gets FDA OK
NMD Pharma has been cleared by the U.S. Food and Drug Administration (FDA) to start a Phase 2b clinical…
Articles by Margarida Maia, PhD
Enspryng eases gMG symptoms in Phase 3 trial, but falls short of hopes
Enspryng (satralizumab), which Chugai Pharmaceutical is testing for generalized myasthenia gravis (gMG), showed a significant benefit in…
High levels of immune protein linked to MG severity, relapse risk
Higher levels of an immune protein called macrophage migration inhibitory factor (MIF) in the blood are linked to more severe…
Triamcinolone injections around the eyeballs seen to ease ocular MG
Periocular (around-the-eyeball) injections of triamcinolone, a corticosteroid, may ease early symptoms of ocular myasthenia gravis (MG) and reduce the…
TOL2 tolerated well in preclinical study
TOL2, a medication being developed by Toleranzia for the treatment of myasthenia gravis (MG), was found to be…
Top 10 myasthenia gravis stories of 2023
In 2023, Myasthenia Gravis News brought up-to-date coverage of the latest scientific research and developments in the treatment of…
Vyvgart listed for reimbursement in China for adults with gMG
Vyvgart (efgartigimod alfa) has been listed on China’s 2023 National Reimbursement Drug List (NRDL) as a treatment for adults…
IVIG during pregnancy found to ease MG symptoms in newborn
Treatment with intravenous immunoglobulin (IVIG) during pregnancy may have helped ease symptoms of a fetal disorder in a girl…
Povetacicept may be superior to current MG treatments: Early study
The experimental treatment povetacicept (ALPN-303) may be more effective than current available treatments for myasthenia gravis (MG), according to…
Personality traits in MG patients may underlie depression, anxiety
Negative emotions, a personality trait known as neuroticism, are more likely in people with myasthenia gravis (MG) than those without…